The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1107-1113

  Morgan, Kelly J ^a   Rowley, Matthew A ^a   Wiesner, Stephen M ^a   Hasz, Diane E ^a   Van Ness, Brian ^a   Largaespada, David A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

GAP related domain; Myeloid leukemia; Neurofibromin; Ras

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROFIBROMIN; RAS PROTEIN; GUANOSINE TRIPHOSPHATE; PROTEIN P21;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; GENE ACTIVATION; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN DOMAIN; ANIMAL; CELL CULTURE; DOWN REGULATION; HUMAN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DOWN-REGULATION; GTPASE-ACTIVATING PROTEINS; GUANOSINE TRIPHOSPHATE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, SCID; NEUROFIBROMIN 1; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR CELLS, CULTURED;

EID: 85053235635     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.12.015     Document Type: Article

References (32)

1. Rasmussen S.A., Yang Q., and Friedman J.M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68 5 (2001) 1110-1118
2. Side L.E., Emanuel P.D., Taylor B., Franklin J., Thompson P., Castleberry R.P., et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92 1 (1998) 267-272
3. Stiller C.A., Chessells J.M., and Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 70 5 (1994) 969-972
4. Emanuel P.D., Shannon K.M., and Castleberry R.P. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today 2 11 (1996) 468-475
5. Gadner H., and Haas O.A. Experience in pediatric myelodysplastic syndromes. Hematol Oncol Clin N Am 6 3 (1992) 655-672
6. Bedigian H.G., Johnson D.A., Jenkins N.A., Copeland N.G., and Evans R. Spontaneous and induced leukemias of myeloid origin in recombinant inbred BXH mice. J Virol 51 3 (1984) 586-594
7. Largaespada D.A., Shaughnessy Jr. J.D., Jenkins N.A., and Copeland N.G. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 69 8 (1995) 5095-5102
8. Jacks T., Shih T.S., Schmitt E.M., Bronson R.T., Bernards A., and Weinberg R.A. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7 3 (1994) 353-361
9. Largaespada D.A., Brannan C.I., Jenkins N.A., and Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 12 2 (1996) 137-143
10. Le D.T., Kong N., Zhu Y., Lauchle J.O., Aiyigari A., Braun B.S., et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103 11 (2004) 4243-4250
11. Xu G.F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63 4 (1990) 835-841
12. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63 4 (1990) 843-849
13. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69 2 (1992) 265-273
14. Ohba Y., Mochizuki N., Yamashita S., Chan A.M., Schrader J.W., Hattori S., et al. Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3. J Biol Chem 275 26 (2000) 20020-20026
15. Arun D., and Gutmann D.H. Recent advances in neurofibromatosis type 1. Curr Opin Neurol 17 2 (2004) 101-105
16. Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., and Lowy D.R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP Ras. Proc Natl Acad Sci USA 90 12 (1993) 5539-5543
17. Griesser J., Kaufmann D., Eisenbarth I., Bauerle C., and Krone W. Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1). Biol Chem Hoppe Seyler 376 2 (1995) 91-101
18. Corral T., Jimenez M., Hernandez-Munoz I., Perez de Castro I., and Pellicer A. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity. J Cell Physiol 197 2 (2003) 214-224
19. Hiatt K.K., Ingram D.A., Zhang Y., Bollag G., and Clapp D.W. Neurofibromin GTPase activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem 276 10 (2001) 7240-7245
20. Li Y., and White R. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Cancer Res 56 12 (1996) 2872-2876
21. Flotho C., Valcamonica S., Mach-Pascual S., Schmahl G., Corral L., Ritterbach J., et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13 1 (1999) 32-37
22. Wiesner S.M., Jones J.M., Hasz D.E., and Largaespada D.A. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood 106 3 (2005) 1054-1062
23. Rowley M., and Van Ness B. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. Oncogene 21 57 (2002) 8769-8775
24. Johnson M.R., DeClue J.E., Felzmann S., Vass W.C., Xu G., White R., et al. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 14 1 (1994) 641-645
25. Kersey J.H., Wang D., and Oberto M. Resistance of t(4; 11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia 12 10 (1998) 1561-1564
26. Chin L., Tarn A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400 6743 (1999) 468-472
27. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15 24 (2001) 3249-3262
28. Jonkers J., and Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6 6 (2004) 535-538
29. Schmitt C.A., Rosenthal C.T., and Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6 9 (2000) 1029-1035
30. Musgrove E.A. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24 1 (2006) 13-19
31. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast ERA proteins. Cell 63 4 (1990) 851-859
32. Malumbres M., and Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 3 (1998) d887-d912